Comparison of Buserelin to Danazol Therapy in Endometriosis

In: GnRH Analogues in Cancer and Human Reproduction · 1990 · pp. 17–31 · doi:10.1007/978-94-009-2169-6_3 · W4252201387
book-chapter OA: closed CC0
Full text JSON View on OpenAlex View at publisher
AI-generated summary by claude@2026-06+body, 2026-06-13

This paper compares buserelin, an LH-RH agonist, to danazol in treating endometriosis, acknowledging the disease's sensitivity to ovarian steroids and its relationship with reproductive years and menopause.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-06 · read from full text

This paper compares buserelin with danazol therapy for endometriosis, focusing on hormonal suppression effects as treatment for the condition, drawing on a structured buserelin protocol study group. It describes approaches in which gonadotropin-releasing hormone agonist–mediated reversible hypogonadism is evaluated against danazol’s endocrine effects, with the key finding centered on comparative efficacy within endometriosis populations treated under these regimens. The paper’s main caveat is that its evidence base reflects protocol-based therapeutic comparisons and the era’s trial designs, with outcomes influenced by endocrine variability rather than offering mechanistic confirmation of lesion etiology. This paper is centrally about endometriosis — it directly compares buserelin to danazol therapy for endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 6,700 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Abstract

Although the etiology of endometriosis is not understood, it is known that the ectopic endometrial tissue is sensitive to the production of sex steroid hormones during the menstrual cycle. Endometriosis is rare before menarche and develops usually during the reproductive years. The importance of ovarian steroids in the development and maintenance of endometriosis is also demonstrated by the usual curative effect of oophorectomy and the spontaneous regression of the disease at menopause. Experimentally implanted endometriosis in castrated monkeys requires sex steroids for its maintenance [1]. Preview Unable to display preview. Download preview PDF. Similar content being viewed by others

References

Dizerega, GS, Barber, DL, and Hodgen, GD (1980). Endometriosis: Role of ovarian steroids in initiation, maintenance and suppression. Fertil Steril, 33, 649 Bergquist, A, Ljungberg, O, and Myhre, E (1984). Comparison of the histological appearance of human endometrium and endometriotic tissue obtained simultaneously: A preliminary report. Acta Obstet Gynecol Scand (Suppl), 123, 11 Janne, O, Kauppila, A, and Kokko, E (1981). Estrogen and progestin receptors in endometriotic lesions: comparison with endometrial tissue. Am J Obstet Gynecol, 141, 562 Tamaya, T, Motoyama, T, and Ohono, Y (1979). Steroid receptor levels and histology of endometriosis and adenomysis. Fertil Steril, 31, 396 Vihko, R, Isotalo, H, and Kauppila, A (1984). Hormonal regulation of endometrium and endometriosis tissue. In: Raynaud, OP (ed.) “Medical Management of Endometriosis”, p 79. (New York: Raven Press) Kistner, RW (1958). The use of newer progestins in the treatment of endometriosis. Am J Obstet Gynecol, 75, 264 Kistner, RW (1959). The treatment of endometriosis by inducing pseudopregnancy with ovarian hormones: a report of 58 cases. Fertil Steril, 10, 539 Dmowski, WP, and Cohen, MR (1978). Antigonadotropin (danazol) in the treatment of endometriosis. Am J Obstet Gynecol, 130, 41 Barbieri, RL, Evans, S, and Kistner, RW (1982). Danazol in the treatment of endometriosis: analysis of of 100 cases with a 4-year follow-up. Fertil Steril, 36, 737 Buttram, VC, Reiter, RC, and Ward, S (1985). Treatment of endometriosis with danazol: report of a six year prospective study. Fertil Steril, 43, 353 Lemay, A, and Quesnel, G (1982). Potential new treament of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormonereleasing hormone (LH-RH) agonist. Fertil Steril, 38, 376 Shaw, RW, Fraser, HM, and Boyle, H (1983). Intranasal treatment with luteinizing hormone releasing hormone agonist in women with endometriosis. Brit Med J, 287, 1667 Pring, DW, Maresh, M, and Fraser, AC (1983). Luteinizing hormone releasing hormone agonist in women with endometriosis. Brit Med J, 287, 1718 Lemay, A, Maheux, R, Faure, N, Jean, C, and Fazekas, ATA (1984). Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (buserelin) as a new therapeutic approach for endometriosis. Fertil Steril, 41, 863 Schriock, E, Monroe, SE, Henzl, M, and Jaffe, RB (1985). Treatment of endometriosis with a potent agonist of gonadotropinreleasing hormone (nafarelin). Fertil Steril, 44, 583 Zorn, JR, Tanger, Ch, Roger, M, Grenier, J, Comaru-Schally, AM, and Schally, AV (1986). Therapeutic hypogonadism induced by a delayed-release preparation of microcapsules of D-Trp-6-luteinizing hormone-releasing hormone: A preliminary study in eight women with endometriosis. Int J Fertil, 3, 11 Hardt, W, Schimdt-Gollwitzer, M, Schmidt-Gollwitzer K, Genz, T, and Nevinny-Stickel, J (1986). Erst ergebnisse bei der behandlung der endometriose mit dem LH-RH-analogon buserelin. Geburtsh u Frauenheilk, 46, 483 Steingold, KA, Cedars, M, Ju, JKH, Randle, D, Judd, HL, and Meldrum, DR (1987). Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. Obstet Gynecol, 69, 403 Lemay, A, Maheux, R, Huot, C, Blanchet, J, and Faure, N (1988). Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. Am J Obstet Gynecol (in press) American Fertility Society (1979). Classification of endometriosis. Fertil Steril, 32, 633 Fraser, IS, Markham, R, Mcllveen, J, and Robinson, M (1982). Dynamic tests of hypothalamic and pituitary function in women treated with danazol. Fertil Steril 37, 484 Dmowski, PW, Headley, S, and Radwanska, E (1983). Effects of danazol on pulsatile gonadotropin patterns and on serum estradiol levels in normally cycling women. Fertil Steril, 39, 49 Rannevik, G, and Thorell, JI (1984). The influence of danazol on pituitary function and on the ovarian follicular hormone secretion in premenopausal women. Acta Obstet Gynecol Scand (Suppl), 123, 89 Hardt, W, and Schmidt-Gollwitzer, M (1983). Sustained gonadal suppression in fertile women with the LHRH agonist buserelin. Clin Endocrinol, 19., 613 Meldrum, DR, Pardridge, WM, Karow, WG, Rivier, J, Vale, W, and Judd, HL (1983). Hormonal effects of danazol and medical oophorectomy in endometriosis. Obstet Gynecol, 62, 480 Holt, JP, and Keller, D (1984). Danazol treatment increases serum enzyme levels. Fertil Steril, 41, 70 Cann, CE, Henzl, M, Burry, K, Andreko, J, Hanson, F, Adamson, D, Trobough, G, and Strewler, G (1986). Reversible bone loss is induced by GnRH agonist. 68th Annual Meeting of the Endocrine Society, Anaheim, California, Abstract Matta, WH, Shaw, RW, Hesp, R, and Katz, D (1987). Hypogonadism induced by luteinizing hormone releasing hormone agonist analogues: effects on bone density in premenopausal women. Brit Med J, 294. 1523 Devogelaer, JP, DeDeuxchaisnes, CN, Donnez, J, and Thomas, K (1987). LHRH analogues and bone loss. The Lancet, I 1498 Author information Authors and Affiliations Consortia Editor information Editors and Affiliations Rights and permissions Copyright information © 1990 Springer Science+Business Media Dordrecht About this chapter Cite this chapter Lemay, A., HRPI buserelin protocol 310 study group. (1990). Comparison of Buserelin to Danazol Therapy in Endometriosis. In: Vickery, B.H., Lunenfeld, B. (eds) GnRH Analogues in Cancer and Human Reproduction. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-2169-6_3 Download citation DOI: https://doi.org/10.1007/978-94-009-2169-6_3 Publisher Name: Springer, Dordrecht Print ISBN: 978-94-010-7474-2 Online ISBN: 978-94-009-2169-6 eBook Packages: Springer Book Archive

Keywords

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (28)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK